Fig. 5

Co-targeting of CDK9 and MRE11 is toxic to prostate cancer cells. Data presented is always from at least three biological replicates and Student’s t-test was used to assess the statistical significance. A Combined inhibition of CDK9 and MRE11 combinatorically inhibits proliferation of CRPC cells (C4-2 and 22RV1) as determined using cell viability assay. B Combined inhibition of CDK9 and MRE11 blocks the colony-formation of 22RV1 cells. Cells were treated with 2.5 nM NVP2 either in the presence or absence of 10 µM Mirin. Left: example of colony-formation after seven days. Right: To get the average and SEM of four biological replicates, crystal violet dye was extracted and absorbance measured. Student’s t-test was used to assess the statistical significance. C Knockdown (KD) of both CDK9 and MRE11 significantly suppresses proliferation of CRPC cells. KD was performed for 4 days after which western blot was used to confirm silencing, and viability assays were used to evaluate effects on proliferation